OUR MEDICAL SPECIALISTS  >  DEPARTMENT OF MOLECULAR BIOLOGY & CELLULAR BIOTHERAPY CENTER

Prof. Han Weidong, MD, PhD

Director of Biotherapeutic Center · National CAR-T Translation Pioneer  |  Chinese PLA General Hospital (301 Hospital)

Prof. Han Weidong, MD, PhD
DIRECTOR OF BIOTHERAPEUTIC CENTER · NATIONAL CAR-T TRANSLATION PIONEER

Prof. Han Weidong, MD, PhD

Department of Molecular Biology & Cellular Biotherapy Center
Chinese PLA General Hospital (301 Hospital)
  • Hospital Affiliation
    Chinese PLA General Hospital (301 Hospital)
  • Clinical Specialty
    Cellular Immunotherapy, CAR-T & Solid Tumor Cell Translation
  • Clinical Languages
    English, Mandarin
  • Clinical Experience
    30+ Years
  • Consultation Turnaround
    24–48 Hours Priority Review
Request Specialist Review →
ACCREDITED CHAIR PROFILE & CLINICAL OVERVIEW

Foremost Pioneer in CAR-T Engineering for Hematologic Malignancies and Solid Tumors

Prof. Han Weidong, MD, PhD, is Director of the Department of Molecular Biology and Biotherapeutic Center at the Chinese PLA General Hospital (301 Hospital). Internationally acclaimed as one of the world's most prolific cellular immunotherapy trial leaders, Prof. Han has been instrumental in placing China at the global vanguard of chimeric antigen receptor (CAR) T-cell therapy.

Prof. Han led China's earliest registered CAR-T clinical trials, expanding beyond classical CD19/CD20/BCMA hematologic designs into solid tumors. He was among the first worldwide to demonstrate objective clinical responses using EGFR-, CD133-, and Claudin 18.2-targeted CAR-T cells in advanced glioblastoma, cholangiocarcinoma, and gastric cancer.

Operating from 301 Hospital's State Key Laboratory platform, Prof. Han's research tackles the toughest hurdles in immunotherapy: tumor antigen heterogeneity, immunosuppressive microenvironments, and T-cell exhaustion. His innovative sequential infusion and checkpoint-synergized CAR-T regimens have provided durable remissions for international patients who exhausted standard systemic therapies.

Primary Appointment Director, Biotherapeutic Center, Chinese PLA General Hospital (301 Hospital)
Academic Honor National Science Fund for Distinguished Young Scholars; Leading Talent in S&T Innovation
Professional Governance Vice Chair, Biotherapy Committee of Chinese Anti-Cancer Association
International Standing Member, American Society of Gene & Cell Therapy (ASGCT); International Society for Cell & Gene Therapy (ISCT)
CORE OPERATIVE MASTERY & CLINICAL EXCELLENCE

Procedural Frontiers & Department Innovations

Solid Tumor CAR-T Translation

First-in-human translation of CAR-T targeting specific solid tumor cell surface markers, achieving unprecedented tumor regression in refractory GI and brain cancers.

Sequential Cocktails for Leukemia / Lymphoma

Developed sequential CD19 followed by CD22 or CD20 CAR-T infusions, eliminating escape variants and raising long-term leukemia cure rates.

Microenvironment-Armored CARs

Engineered 4th-generation CAR-T constructs secreting localized cytokines and blockade nanobodies to neutralize inhibitory TGF-beta and PD-L1 barriers.

Severe CRS Predictive Telemetry

Designed rapid-turnaround serum cytokine profiling algorithms enabling pre-emptive cytokine suppression without compromising CAR-T cell persistence.

ACADEMIC AWARDS & LANDMARK TREATISES

Distinguished National & International Recognition

J CLIN ONCOL
CAR-T Cell Therapy in Relapsed B-Cell Malignancies
High-impact clinical trial establishing sustained complete remission rates in refractory cohorts.
CLIN CANCER RES
EGFR-Targeted CAR-T in Advanced Solid Malignancies
Landmark translational paper demonstrating objective tumor shrinkage in metastatic disease.
MOLECULAR THERAPY
Overcoming Immunosuppression with Armored CAR-T Constructs
Definitive preclinical and clinical proof of next-generation synthetic receptor enhancement.
NATIONAL AWARD
Military & National Medical Science Award (1st Class)
Conferred for monumental achievements in pioneering national biotherapeutic cell therapy.

CASE INTAKE & CELLULAR IMMUNOTHERAPY TRIAGE

Request a CAR-T Immunotherapy Review with Prof. Han Weidong, MD, PhD

Submit recent pathology/biopsy tissue reports, flow cytometry/IHC for surface antigens (CD19/BCMA/Claudin18.2), PET-CT/MRI scans, and past immunotherapy records for direct evaluation by Prof. Han Weidong. Our medical team responds within 24–48 hours.

    Prof. Han Weidong, MD, PhD